CA2982217A1 - Pyridopyrimidinones and their use as nmda receptor modulators - Google Patents
Pyridopyrimidinones and their use as nmda receptor modulators Download PDFInfo
- Publication number
- CA2982217A1 CA2982217A1 CA2982217A CA2982217A CA2982217A1 CA 2982217 A1 CA2982217 A1 CA 2982217A1 CA 2982217 A CA2982217 A CA 2982217A CA 2982217 A CA2982217 A CA 2982217A CA 2982217 A1 CA2982217 A1 CA 2982217A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrido
- pyrimidin
- oxo
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/076617 | 2015-04-15 | ||
| CN2015076617 | 2015-04-15 | ||
| PCT/EP2016/057962 WO2016166078A1 (en) | 2015-04-15 | 2016-04-12 | Pyridopyrimidinones and their use as nmda receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2982217A1 true CA2982217A1 (en) | 2016-10-20 |
Family
ID=55809078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2982217A Abandoned CA2982217A1 (en) | 2015-04-15 | 2016-04-12 | Pyridopyrimidinones and their use as nmda receptor modulators |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10280165B2 (https=) |
| EP (1) | EP3283487B1 (https=) |
| JP (2) | JP6847851B2 (https=) |
| KR (1) | KR20170137137A (https=) |
| CN (1) | CN107531696B (https=) |
| AU (1) | AU2016248886B2 (https=) |
| BR (1) | BR112017021083A2 (https=) |
| CA (1) | CA2982217A1 (https=) |
| CL (1) | CL2017002498A1 (https=) |
| CO (1) | CO2017009989A2 (https=) |
| CR (1) | CR20170462A (https=) |
| IL (1) | IL254921B (https=) |
| MX (1) | MX373162B (https=) |
| PE (1) | PE20180316A1 (https=) |
| PH (1) | PH12017501876A1 (https=) |
| RU (1) | RU2717665C2 (https=) |
| SG (1) | SG11201708294YA (https=) |
| UA (1) | UA120647C2 (https=) |
| WO (1) | WO2016166078A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016004540A (es) | 2013-10-11 | 2016-07-21 | Hoffmann La Roche | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). |
| EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
| SMT202000534T1 (it) | 2015-12-09 | 2020-11-10 | Cadent Therapeutics Inc | Modulatori eteroaromatici del recettore nmda e loro usi |
| ES2975336T3 (es) | 2016-12-22 | 2024-07-04 | Novartis Ag | Moduladores del receptor NMDA y usos de los mismos |
| BR112021001967A2 (pt) | 2018-08-03 | 2021-04-27 | Cadent Therapeutics, Inc. | moduladores de receptor nmda heteroaromáticos e usos dos mesmos |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| PE20230609A1 (es) | 2020-05-04 | 2023-04-13 | Amgen Inc | Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2004113335A2 (en) * | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| AR065194A1 (es) * | 2007-02-05 | 2009-05-20 | Xenon Pharmaceuticals Inc | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio |
| JP6130061B2 (ja) * | 2013-06-19 | 2017-05-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体 |
| MX2016004540A (es) * | 2013-10-11 | 2016-07-21 | Hoffmann La Roche | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). |
| EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
-
2016
- 2016-04-12 EP EP16718618.8A patent/EP3283487B1/en active Active
- 2016-04-12 CA CA2982217A patent/CA2982217A1/en not_active Abandoned
- 2016-04-12 RU RU2017139254A patent/RU2717665C2/ru active
- 2016-04-12 KR KR1020177032061A patent/KR20170137137A/ko not_active Ceased
- 2016-04-12 AU AU2016248886A patent/AU2016248886B2/en not_active Ceased
- 2016-04-12 PE PE2017002006A patent/PE20180316A1/es unknown
- 2016-04-12 CR CR20170462A patent/CR20170462A/es unknown
- 2016-04-12 JP JP2017553877A patent/JP6847851B2/ja active Active
- 2016-04-12 CN CN201680021960.3A patent/CN107531696B/zh active Active
- 2016-04-12 MX MX2017013101A patent/MX373162B/es active IP Right Grant
- 2016-04-12 SG SG11201708294YA patent/SG11201708294YA/en unknown
- 2016-04-12 WO PCT/EP2016/057962 patent/WO2016166078A1/en not_active Ceased
- 2016-04-12 UA UAA201711077A patent/UA120647C2/uk unknown
- 2016-04-12 BR BR112017021083-5A patent/BR112017021083A2/pt not_active IP Right Cessation
-
2017
- 2017-09-29 CO CONC2017/0009989A patent/CO2017009989A2/es unknown
- 2017-10-03 CL CL2017002498A patent/CL2017002498A1/es unknown
- 2017-10-08 IL IL254921A patent/IL254921B/en active IP Right Grant
- 2017-10-13 PH PH12017501876A patent/PH12017501876A1/en unknown
- 2017-10-13 US US15/783,373 patent/US10280165B2/en active Active
-
2020
- 2020-12-03 JP JP2020200946A patent/JP2021046428A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA120647C2 (uk) | 2020-01-10 |
| AU2016248886A1 (en) | 2017-10-12 |
| RU2017139254A (ru) | 2019-05-15 |
| CR20170462A (es) | 2018-02-01 |
| JP2021046428A (ja) | 2021-03-25 |
| RU2717665C2 (ru) | 2020-03-24 |
| PE20180316A1 (es) | 2018-02-09 |
| JP2018511627A (ja) | 2018-04-26 |
| RU2017139254A3 (https=) | 2019-09-30 |
| US10280165B2 (en) | 2019-05-07 |
| EP3283487B1 (en) | 2019-10-16 |
| HK1245259A1 (zh) | 2018-08-24 |
| SG11201708294YA (en) | 2017-11-29 |
| AU2016248886B2 (en) | 2020-09-10 |
| CN107531696B (zh) | 2021-03-16 |
| IL254921B (en) | 2021-02-28 |
| EP3283487A1 (en) | 2018-02-21 |
| CN107531696A (zh) | 2018-01-02 |
| CO2017009989A2 (es) | 2018-01-05 |
| WO2016166078A1 (en) | 2016-10-20 |
| JP6847851B2 (ja) | 2021-03-24 |
| MX373162B (es) | 2020-04-21 |
| MX2017013101A (es) | 2018-01-30 |
| CL2017002498A1 (es) | 2018-04-20 |
| US20180127414A1 (en) | 2018-05-10 |
| BR112017021083A2 (pt) | 2018-07-03 |
| PH12017501876A1 (en) | 2018-02-26 |
| IL254921A0 (en) | 2017-12-31 |
| KR20170137137A (ko) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2982217A1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
| CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
| EP4497751A1 (en) | Substituted bridged ring inhibitor, preparation method therefor and application thereof | |
| CA2926830C (en) | Thiazolopyrimidinones as modulators of nmda receptor activity | |
| WO2020020189A1 (en) | Compounds as neurokinin-1 receptor antagonists and uses thereof | |
| JP7352294B2 (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| JP2020502047A (ja) | Ｍａｇｌ阻害剤 | |
| KR20200081424A (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| EP3992195A1 (en) | Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof | |
| EP3697781A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| KR20250164854A (ko) | 치환된 인다졸 프로피온산 유도체 화합물 및 ampk 활성제로서의 이의 용도 | |
| JP7041141B2 (ja) | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| TW201331202A (zh) | ［１，２，４］三唑并吡啶及其作為磷酸二酯酶抑制劑之用途 | |
| CN118772126A (zh) | 四元环类衍生物调节剂、其制备方法和应用 | |
| TW202330534A (zh) | 吡唑並環化合物及其應用 | |
| JP2015006994A (ja) | ジヒドロイミダゾオキサゾール誘導体 | |
| HK1245259B (zh) | 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途 | |
| WO2026055419A1 (en) | Modulators of g protein-coupled receptor 88 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210407 |
|
| FZDE | Discontinued |
Effective date: 20231012 |